BRCA1 and myeloproliferative disorder: To our knowledge, this therapeutic approach of combining PARP inhibitors with IFNα has not been investigated yet and holds potential for application in non-familial MPN patients as well, as BRCA1 is epigenetically inactivated in 40% of all MPN samples analyzed [22], and alterations in DNA repair genes are a frequent feature in MPN patients [27].